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DO PEOPLE CONSIDER THE EFFECTS OF 
ILL-HEALTH ON INCOME AND LEISURE WHEN
ANSWERING HEALTH-RELATED QUALITY-
OF-LIFE QUESTIONS?
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OBJECTIVES: The objective of the present study was to
evaluate whether people do include the effects of ill-health
on income and leisure in quality of life valuation when
the measure is silent on both. METHODS: A convenience
sample of 20 health professionals (5 medical doctors, 2
medical researchers, and 13 nurses) were administered a
questionnaire that described the health status of a 30-year
old male patient suffering from multiple sclerosis (MS).
Respondents rated that health status on a visual analogue
scale (VAS) and were thereafter asked whether the impact
of ill-health on income and leisure was included in their
valuation. In case either answer was negative, they were
explicitly asked to consider these effects in a second VAS
question. RESULTS: Twelve (60%) respondents did not
consider the effects of ill-health on income whereas only
5 (25%) respondents did not consider the effects of ill-
health on leisure. The mean VAS score was signiﬁcantly
higher among respondents who did not consider income
(48.33 versus 31.25, p = 0.036). Among those who did
not considered leisure or income in the ﬁrst VAS ques-
tion, the mean VAS of the second question was signiﬁ-
cantly lower (mean difference 7.89, p = 0.005). However,
5 respondents (25%) who did not consider income in the
ﬁrst VAS question did not change their VAS score in 
the second question. CONCLUSIONS: The majority of
respondents did not consider the effects of ill-health on
income but on leisure. Moreover, respondents may not
include the effects of ill-health on income even when they
are explicitly asked to do so. Our results are in line with
the argument that productivity costs related to paid work
should be included as costs whereas productivity costs
related to leisure time should be captured in the QALY.
Still, health state valuations may need to be more explicit
in this respect.
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OBJECTIVE: To estimate the costs of multiple sclerosis
(MS) in Poland according to severity of disease.
METHODS: Enrolled were 148 outpatients with MS at
3 centres across Poland. Socio-demographic, clinical and
resource utilization data were collected using a validated
questionnaire over a 5-month period. Total, direct and
indirect costs were compared among three groups cate-
gorised by disease severity (EDSS score): stages I, II and
III, corresponding to mild (EDSS 1–3, 5, n = 57), moder-
ate (EDSS 4–6, n = 56) and severe (EDSS 6, 5–8, n = 35)
MS, respectively. Cost evaluation was performed from
both the public payer and societal perspective. Due to
absence of available opportunity costs, tariffs were used
as an approximation. Human capital approach was used
for calculation of indirect costs. Simple sensitivity analy-
sis was performed by varying the tariffs, valuing caregiv-
ing at 40% of the average wage and taking into account
extreme values of direct and indirect costs in each group.
RESULTS: From the societal perspective the mean total
cost /patient/d was estimated at 71,109 and 132 PLN for
stage I, II, and III respectively (1 PLN = €4). Regardless
of EDSS stage indirect costs exceeded direct costs and
were estimated at 46, 73, and 84 PLN/patient/d for stage
I, II, and III respectively. The increase of total, direct
medical and indirect costs associated with progression of
disease was statistically signiﬁcant. The major medical
cost drivers were rehabilitation and hospitalizations. The
percentage of direct costs covered by public payer was
80% for stage I and II and 60% for stage III. Results were
sensitive to the variation applied, but the overall trend
remained as in the primary analysis. CONCLUSION:
This study conﬁrms that MS represents a high economic
burden, with indirect costs greatly exceeding direct costs.
As costs increase with disease progression, treatment
efforts should focus on patients in the early stages of MS.
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OBJECTIVE: Assess utilization of Dysport and BOTOX
for cervical dystonia and blepharospasm and compute the
cost consequences of toxin selection. METHODS: Six
European study sites abstracted drug utilization data
from the records of their patients who had received
Dysport then BOTOX or BOTOX then Dysport in a drug
crossover that occurred in clinical practice. To reduce
potential selection bias and confounding variables,
patient records were screened for study inclusion/exclu-
sion criteria during scheduled clinic visits. Patients were
screen-qualiﬁed if they were ≥18 years of age, medically
